Turner, Nicholas http://orcid.org/0000-0001-8937-0873
Dent, Rebecca A.
O’Shaughnessy, Joyce
Kim, Sung-Bae
Isakoff, Steven J.
Barrios, Carlos
Saji, Shigehira
Bondarenko, Igor
Nowecki, Zbigniew
Lian, Qinshu
Reilly, Sarah-Jayne
Hinton, Heather
Wongchenko, Matthew J.
Kovic, Bruno
Mani, Aruna
Oliveira, Mafalda
Clinical trials referenced in this document:
Documents that mention this clinical trial
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
https://doi.org/10.1007/s10549-021-06450-x
Funding for this research was provided by:
Genentech/Roche
F. Hoffmann-La Roche
Article History
Received: 22 April 2021
Accepted: 12 November 2021
First Online: 3 December 2021
Declarations
:
: N Turner has received honoraria for advisory/consultancy from AstraZeneca, Bristol-Myers Squibb, Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, Roche/Genentech, Bicycle Therapeutics, Taiho, Zeno pharmaceuticals, Repare therapeutics; research grant/funding (to institution) from AstraZeneca, BioRad, Pfizer, Roche/Genentech, Clovis, Merck Sharpe and Dohme, Guardant Health. RA Dent has received honoraria from Roche, Novartis, Lilly, Pfizer, Eisai, Merck, AstraZeneca; travel/accommodation/expenses from AstraZeneca, Merck, Pfizer, Roche. J O’Shaughnessy has received honoraria for advisory/consultancy from AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeutics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Odonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals, Takeda. S-B Kim has served as an advisor/consultant for Novartis, AstraZeneca, Lilly, Enzychem Lifesciences, Dae Hwa Pharmaceutical Co. Ltd, ISU Abxis, Daiichi-Sankyo; research grants/funding (to institution) from Novartis, Sanofi-Aventis, Kyowa-Kirin Inc, DongKook Pharm Co. SJ Isakoff has served as an advisor/consultant for Genentech, AbbVie, Hengrui, Immunomedics, Mylan, Puma, Oncopep Research; research grants/funding (to institution) from Genentech, AbbVie, Oncopep, AstraZeneca, Merck. C Barrios has received honoraria for advisory/consultancy roles from Boehringer Ingelheim, GSK, Novartis, Pfizer, Lilly, Roche/Genentech, Eisai, MSD, AstraZeneca, Bayer; research grants/funding (to institution) from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Celgene, Covance, Lilly, Medivation, Merck Serono, MSD, Novartis, Pfizer, PharmaMar, Roche/Genentech; travel/accommodation/expenses from Boehringer Ingelheim, GSK, Novartis, Pfizer, Lilly, Roche/Genentech, Eisai, MSD, AstraZeneca, Bayer. S Saji has received honoraria from Chugai, Eisai, AstraZeneca, Takeda, Novartis, Kyowa-Kirin, Eli Lilly, MSD, Pfizer; has served as an advisory/consultant for Chugai, Novartis, Kyowa-Kirin; research grants/funding (to institution) from Chugai, Eisai, Takeda, Novartis, Daiichi-Sankyo, Taiho Pharmaceutical. I Bondarenko reports no disclosures. Z Nowecki has received travel/accommodation/expenses from Roche. Q Lian is an employee of GNE/Roche and holds stocks/shares in Roche. S-J Reilly is an employee of Roche Products Ltd and holds shares in Roche. H Hinton is an employee of F. Hoffmann-La Roche Ltd and holds shares in Roche. MJ Wongchenko is an employee of Genentech and holds shares in Roche. B Kovic is an employee of Hoffmann-La Roche Limited. A Mani is an employee of Genentech and holds shares in Roche. M Oliveira has served as an advisor/consultant for GNE, GSK, PUMA Biotechnology, Roche, Seattle Genetics, Novartis; research grants/funding (to institution) from GNE, GSK, PUMA Biotechnology, Roche, Seattle Genetics, Novartis, Philips, AstraZeneca, Immunomedics, Boehringer Ingelheim, Zenith Epigenetics, Cascadian Therapeutics, Sanofi, Celldex, Bayer, Piqur; member of the executive board of the SOLTI Breast Cancer Research Group (non-remunerated).
: The study protocol was approved by an institutional review board or independent ethics committee at each site. The trial was carried out in accordance with the principles of the International Conference on Harmonisation Guidelines for Good Clinical Practice, the Declaration of Helsinki, and all applicable national and local laws.
: All patients provided written informed consent.
: All patients participating in the trial provided written informed consent.